Artichoke (Cynara scolymus L.) water extract alleviates palmitate-induced insulin resistance in HepG2 hepatocytes via the activation of IRS1/PI3K/AKT/FoxO1 and GSK-3β signaling pathway

BMC Complement Med Ther. 2023 Dec 15;23(1):460. doi: 10.1186/s12906-023-04275-3.

Abstract

Background: Artichoke (Cynara scolymus L.) is a typical element of a traditional Mediterranean diet and has potential health advantages for insulin resistance (IR) and type 2 diabetes mellitus (T2DM). This study aims to evaluate the effect and underlying mechanism of artichoke water extract (AWE) on palmitate (PA)-induced IR in human hepatocellular carcinoma (HepG2) cells.

Methods: The effect of AWE on cell viability was determined using CCK8 assay. Cellular glucose uptake, glucose consumption, glucose production, and glycogen content were assessed after AWE treatment. The gene expression and protein levels were examined by real-time polymerase chain reaction (qRT-PCR) and western blotting.

Results: The results showed that AWE dose-dependently increased cell viability in IR HepG2 cells (P < 0.01). AWE treatment significantly promoted glucose uptake and consumption, decreased glucose production, and increased the cellular glycogen content in IR HepG2 cells (P < 0.01). Mechanistically, AWE elevated the phosphorylation and total protein levels of major insulin signaling molecules in IR HepG2 cells, which resulted in a decrease in the expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) and the inhibition of glycogen synthase (GS) phosphorylation in IR HepG2 cells. Furthermore, the protective effect of AWE on IR HepG2 cells might be ascribed to the inhibition of the endoplasmic reticulum (ER) stress.

Conclusion: We conclude that AWE may improve glucose metabolism by regulating IRS1/PI3K/AKT/FoxO1 and GSK-3β signaling associated with the inhibition of ER stress in IR HepG2 cells induced by PA.

Keywords: Artichoke; Gluconeogenesis; Glycogen synthesis; HepG2 cells; Insulin resistance.

MeSH terms

  • Cynara scolymus*
  • Diabetes Mellitus, Type 2*
  • Glucose / metabolism
  • Glycogen / metabolism
  • Glycogen / pharmacology
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Hepatocytes / metabolism
  • Humans
  • Insulin Receptor Substrate Proteins / metabolism
  • Insulin Resistance*
  • Palmitates / pharmacology
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction

Substances

  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • Phosphatidylinositol 3-Kinases
  • Palmitates
  • Glucose
  • Glycogen
  • IRS1 protein, human
  • Insulin Receptor Substrate Proteins

Grants and funding